ORGARAN. Extending the Frontiers of Venous Thrombosis Prophylaxis - Satellite Symposium held during the 13th Congress of the International Society of Thrombosis and Haemostasis (ISHT), Amsterdam, July 1991. Special Topic Issue: Haemostasis 1992, Vol. 22, No. 2 (Paperback)

Orgaran, composed of heparan, dermatan and chondroitin sulfates, is a new antithrombotic agent which shows great therapeutic potential. This proceedings issue discusses Orgaran's pharmacological mechanisms and presents pre-clinical trials as well as clinical trials in patients with heparin-induced thrombocytopenia and patients having hip surgery. In these studies, Orgaran is compared to either placebo or standard low-dose heparin. Results indicate that Orgaran has a particularly long biological half-life and produces less bleeding than heparin or an equivalent anti-thrombotic effect.